- Home
- FTLF vs LPTX Comparison
FTLF vs LPTX Comparison
Compare FTLF & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTLF
- LPTX
- Stock Information
- Founded
- FTLF 2005
- LPTX 2011
- Country
- FTLF United States
- LPTX United States
- Employees
- FTLF N/A
- LPTX N/A
- Industry
- FTLF Medicinal Chemicals and Botanical Products
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTLF Health Care
- LPTX Health Care
- Exchange
- FTLF Nasdaq
- LPTX Nasdaq
- Market Cap
- FTLF 149.3M
- LPTX 119.6M
- IPO Year
- FTLF N/A
- LPTX N/A
- Fundamental
- Price
- FTLF $13.61
- LPTX $0.38
- Analyst Decision
- FTLF Strong Buy
- LPTX Buy
- Analyst Count
- FTLF 2
- LPTX 2
- Target Price
- FTLF $20.50
- LPTX $8.00
- AVG Volume (30 Days)
- FTLF 9.8K
- LPTX 328.6K
- Earning Date
- FTLF 08-13-2025
- LPTX 08-11-2025
- Dividend Yield
- FTLF N/A
- LPTX N/A
- EPS Growth
- FTLF 22.19
- LPTX N/A
- EPS
- FTLF 0.90
- LPTX N/A
- Revenue
- FTLF $63,856,000.00
- LPTX N/A
- Revenue This Year
- FTLF $4.72
- LPTX N/A
- Revenue Next Year
- FTLF $6.61
- LPTX N/A
- P/E Ratio
- FTLF $15.14
- LPTX N/A
- Revenue Growth
- FTLF 9.13
- LPTX N/A
- 52 Week Low
- FTLF $9.83
- LPTX $0.22
- 52 Week High
- FTLF $17.75
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- FTLF 43.17
- LPTX 50.42
- Support Level
- FTLF $13.66
- LPTX $0.38
- Resistance Level
- FTLF $14.54
- LPTX $0.44
- Average True Range (ATR)
- FTLF 0.56
- LPTX 0.04
- MACD
- FTLF -0.11
- LPTX -0.00
- Stochastic Oscillator
- FTLF 20.11
- LPTX 38.74
About FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .